

Transaction news

December 20, 2021

Ne pas distribuer, directement ou indirectement, aux Etats-Unis, au Canada, en Australie ou au Japon.



Cobepa and BioAgilytix to Continue Highly Successful Partnership

New York, NY; Brussels, Belgium; Munich, Germany – Cobepa S.A. is pleased to announce it has extended its partnership with BioAgilytix (“BioAgilytix” or “the Company”) and entered into a recapitalization of the Company in conjunction with Cinven, a leading international private investment firm focused on building world-class global organizations.

Founded in 2008, BioAgilytix is a leading global contract research organization (CRO) providing bioanalytical services to pharmaceutical and biotech companies. With headquarters in Durham, North Carolina, BioAgilytix is a global platform with operations across the United States, Europe and Australia focusing on large molecule bioanalytical services, particularly for fast growing and innovative treatments, such as cell and gene therapies. Cobepa became the majority shareholder of BioAgilytix in 2018 and is pleased to remain a significant investor in the Company.

“As we welcome Cinven into the BioAgilytix family, we are thrilled that Cobepa is staying on with us as a major shareholder for our exciting new chapter,” said Jim Datin, President and CEO of BioAgilytix. “Cobepa has been not only a source of capital to fuel our growth over the last several years, but also a critical thought partner in our never-ending prioritization decisions – from selection of strategic growth avenues, to investing heavily ahead of revenue capture, to hiring decisions and much more. The Cobepa team brought sophistication and rigor to our data and analytics capabilities which now permeate our entire organization. They also challenged us to grow with our customers but not at the expense of our core values. Our team also had incredible support from Cobepa on M&A which profoundly contributed to our success. Our deep relationships with their team and their ongoing support will serve us well as we continue to scale and meet the ever growing needs of our highly innovative customers.”

“We are very pleased to continue our close partnership with the entire BioAgilytix management team.

BioAgilytix has earned its industry leading position through its dual-pronged priorities of exceptional science and a customer-first orientation,” said Peter Connolly, Managing Director and Head of Cobepa North America. “Our partnership with the team over the past several years has been highly rewarding and we could not be more impressed with their accomplishments. We would like to thank all the employees for their dedication to helping their biopharma clients develop some of the most innovative therapies in the world.”

About BioAgilytix

BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina's Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across a number of industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix's team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.

About Cobepa

Based in Brussels, New York, and Munich, Cobepa is a privately-held investment company backed by European families. Cobepa manages a diversified portfolio of private equity investments valued at approximately \$4 billion. Cobepa invests in leading companies with superior business models, sustainable market positions and leading management teams. Cobepa North America is primarily focused on investments in the healthcare, business services, and tech-enabled services sectors as well as situations which might benefit from a nimble investment partner. For more information, visit www.cobepa.com.

About Cinven

Cinven is a leading international private equity firm focused on building world-class global companies. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and Technology, Media and Telecommunications (TMT). Cinven has offices in London, Frankfurt, Paris, Milan, Madrid, New York, Guernsey and Luxembourg.

Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society.

Cinven Capital Management (V) General Partner Limited, Cinven Capital Management (VI) General Partner Limited, Cinven Capital Management (VII) General Partner Limited and Cinven Capital Management (SFF) General Partner Limited are each authorised and regulated by the Guernsey Financial Services Commission, and Cinven Limited, the adviser to the Cinven Funds, is authorised and regulated by the Financial Conduct Authority.

In this press release 'Cinven' means, depending on the context, any of or collectively, Cinven Holdings Guernsey Limited, Cinven Partnership LLP, Cinven (LuxCo1) S. r.l., and their respective Associates (as defined in the Companies Act 2006) and/or funds managed or advised by any of the foregoing.

For additional information on Cinven please visit www.cinven.com and www.linkedin.com/company/cinven/.

Avertissement

Aucune communication ni aucune information relative à la vente par Cobepa des actions D'leteren ne peut être diffusée au public dans un pays dans lequel une obligation d'enregistrement ou d'approbation est requise. Aucune démarche n'a été entreprise ni ne sera entreprise dans un quelconque pays dans lequel de telles démarches seraient requises. L'offre et la vente des actions D'leteren par Cobepa peuvent faire l'objet dans certains pays de restrictions légales ou réglementaires spécifiques. Cobepa n'assume aucune responsabilité au titre d'une violation par une quelconque personne de ces restrictions. Le présent communiqué ne constitue pas un prospectus au sens de la Directive 2003/71/CE du parlement européen et du conseil du 4 novembre 2003, telle que transposée dans chacun des Etats membres de l'Espace Economique Européen (la « Directive Prospectus »). Le présent communiqué ne constitue pas et ne saurait être considéré comme constituant une offre au public, une offre de vente ou une offre de souscription ou comme destiné à solliciter un ordre d'achat ou de souscription dans un quelconque pays. L'offre et la vente des actions D'leteren par Cobepa en Belgique ont été effectuées dans le cadre d'un placement privé, en conformité avec la loi du 16 juin 2006 relative aux offres publiques d'instruments de placement et aux admissions d'instruments de placement à la négociation sur des marchés réglementés. S'agissant des Etats membres de l'Espace Economique Européen autres que la Belgique (les « Etats membres ») ayant transposé la Directive Prospectus, aucune action n'a été entreprise et ne sera entreprise à l'effet de permettre une offre au public des actions D'leteren vendues par Cobepa rendant nécessaire la publication d'un prospectus dans l'un ou l'autre des Etats membres. En conséquence, les actions D'leteren n'ont été offertes ou vendues par Cobepa dans les Etats membres qu'en vertu d'une exemption au titre de la Directive Prospectus.

Au Royaume-Uni, le présent communiqué n'est destiné et ne peut être remis qu'à des personnes qui sont (a) des investisseurs professionnels au sens de l'Article 19(5) du Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (« Financial Promotion Order »), (b) aux « high net worth entities », « unincorporated associations » et autres personnes susceptibles d'en être légalement le destinataire entrant dans le champ d'application de l'Article 49(2)(a) à (d) du Financial Promotion Order. Le présent communiqué ne constitue pas une offre de valeurs mobilières ou une quelconque sollicitation d'achat ou de souscription de valeurs mobilières aux Etats-Unis d'Amérique. Des valeurs mobilières ne peuvent être offertes ou vendues aux Etats-Unis qu'à la suite d'un enregistrement en vertu du U.S. Securities Act de 1933, tel que modifié (le « U.S. Securities Act »), ou dans le cadre d'une exemption à cette obligation d'enregistrement. Les actions D'leteren n'ont pas été et ne seront pas enregistrées au sens du U.S. Securities Act et Cobepa n'a pas l'intention d'enregistrer l'offre mentionnée dans le présent communiqué ou une partie de cette offre aux Etats-Unis d'Amérique ni d'effectuer une quelconque offre publique aux Etats-Unis d'Amérique. Le présent communiqué ne doit pas être publié, transmis ou distribué, directement ou indirectement, sur le territoire des Etats-Unis d'Amérique, du Canada, de l'Australie ou du Japon. Cobepa décline toute responsabilité en cas de violation quelconque de ces restrictions. Aucun contrat ni aucune décision d'investissement ne peut s'appuyer sur le présent communiqué de presse.